Name: The future’s bright, the future’s Oncimmune.
Uploaded: 2022-12-22T16:50:19.696702+00:00
Duration: 1282 s
Channel: Vox Markets

Vox Markets

Indeed in this fascinating interview, CEO Adam Hill explains how this leading immunodiagnostics firm with 1st class expertise in autoantibodies - is becoming increasingly embedded in the drug discovery & pre-clinical testing fabric of many of the world’s largest BioPharma groups.

00:00 What’s been driving the demand & series of new orders within ImmunoINSIGHTS? 
02:25 Importance & scope of Master Services Agreements. 
08:30 Applicability of ONC’s technology to latest new therapies. 
11:30 Possible future investments. 
13:05 Expectations fro FY’23 & beyond. 
16:05 Progress at EarlyCDT Lung & strategic options. 
19:50 Future newsflow.

Indeed in this fascinating interview, CEO Adam Hill explains how this leading immunodiagnostics firm with 1st class expertise in autoantibodies - is becoming increasingly embedded in the drug discovery &amp; pre-clinical testing fabric of many of the world’s largest BioPharma groups.00:00 What’s been driving the demand &amp; series of new orders within ImmunoINSIGHTS? 02:25 Importance &amp; scope of Master Services Agreements. 08:30 Applicability of ONC’s technology to latest new therapies. 11:30 Possible future investments. 13:05 Expectations fro FY’23 &amp; beyond. 16:05 Progress at EarlyCDT Lung &amp; strategic options. 19:50 Future newsflow.

What’s been driving the demand & series of new orders within ImmunoINSIGHTS?

Importance & scope of Master Services Agreements

Applicability of ONC’s technology to latest new therapies

Possible future investments

Expectations fro FY’23 & beyond

Progress at EarlyCDT Lung & strategic options

Future newsflow

https://d3ev5earl6dvd0.cloudfront.net/public-media/videos/005/624/005624/video_BLqdiGR.mov